Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 13/20 | 0.64 |
| ▸ | MAPK12 | P53778 | 13/20 | 0.64 |
| ▸ | MAPK11 | Q15759 | 13/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 13/20 | 0.64 |
| ▸ | GCGR | P47871 | 12/20 | 0.64 |
| ▸ | TEK | Q02763 | 3/20 | 0.61 |
| ▸ | RAF1 | P04049 | 4/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19868853 | 0.88 | MAPK14 (0.74) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL6469323 | 0.85 | MAPK13 (0.79) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL6164173 | 0.85 | MAPK13 (0.79) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL6469680 | 0.84 | MAPK13 (0.69) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL8388860 | 0.84 | MAPK13 (0.77) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL8792345 | 0.83 | MAPK13 (0.60) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL6467858 | 0.82 | MAPK14 (0.74) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL6466475 | 0.81 | NOX1 (0.71) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL17002224 | 0.81 | MAPK14 (0.67) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL6468726 | 0.81 | MAPK14 (0.65) | MAPK13MAPK12MAPK11MAPK14GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846389-A1 | IMIDAZOLE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-10-24 | — | — | EP | disclosed |
| EP-1340756-B1 | NOVEL BETA-LACTAM COMPOUNDS AND PROCESS FOR PRODUCING THE SAME | DAINIPPON SUMITOMO PHARMA CO (JP) | 2007-10-10 | — | — | EP | disclosed |
| US-7163936-B2 | β-lactam compounds and process for producing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-01-16 | — | — | US | disclosed |
| WO-2006082002-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173048-A1 | Imidazole derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2006-08-03 | — | — | US | disclosed |
| US-20040102433-A1 | Novel beta-lactam compounds and process for producing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1340756-A1 | NOVEL BETA-LACTAM COMPOUNDS AND PROECSS FOR PRODUCING THE SAME | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102433-A1 | Novel beta-lactam compounds and process for producing the same | MRPL21, MCRS1, RPS4X | MAPK13 3112/4885MAPK12 2419/4885MAPK11 1514/4885 |
| US-20060173048-A1 | Imidazole derivatives | GRM2, GRM1, GRIN2C | MAPK13 2722/4885MAPK12 2936/4885MAPK11 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.